Clinical Trial Update: Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating DKY709 alone or in combination with PDR001 in patients with advanced solid tumors. The enrolled diseases include non-small cell lung …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Melanoma
• Nasopharyngeal Carcinoma
• Non-small Cell Lung Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• DKY709
• PDR001

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Carcinoma, Non-Small-Cell Lung, Melanoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING